Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Melanoma 1

Interventions

Cyclophosphamide 1492Cisplatin 1415Paclitaxel 1319Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1111Bevacizumab 1031Fluorouracil 895Doxorubicin 792Dexamethasone 748Rituximab 720Capecitabine 717Oxaliplatin 701pembrolizumab 680Etoposide 678Irinotecan 636Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 560Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 428Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Interventional × small molecule inhibitor THX-B × Clear all
NCT01657591 2023-01-19

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
21 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡